The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Recalls on a brand of broccoli and chocolate from December were recently upgraded to Class I, the highest risk level issued ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The snacks are now part of a Class I recall, which is for products with the potential of "serious adverse health consequences ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...

Chocolate-covered nuts, apricots, and raisins recalled by Cal Yee Farm in December were given a Class 1 risk level by the FDA ...

The Food and Drug Administration has upgraded its classification of a broccoli recall initially reported in late December, ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...